Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

Maj-Britt JensenDanish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Correspondence[email protected]

Jens Fabricius KrarupDanish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

Torben Palshof

Henning T. MouridsenDanish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

Bent EjlertsenDanish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ;Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop & Henning Mouridsen. (2018) Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncologica 57:1, pages 3-12.
Read now

G. Guerriero, R. Di Giaimo, O. Hentati, F. Kh. Abdel-Gawad, S. Trocchia, D. Rabbito & G. Ciarcia. (2018) Reproductive expression dynamics and comparative toxicological perspective of beta estrogen receptor gene in the male wall lizard, Podarcis sicula Rafinesque, 1810 (Chordata: Reptilia). The European Zoological Journal 85:1, pages 331-341.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

Citations (2)

Read on this site (2)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date